July 1, 2015: BioAegis Therapeutics Collaboration with Harvard School of Public Health Discovers Plasma Gelsolin Boosts the Immune Response to Pathogens

July 1, 2015

Dr. Lester Kobzik, Professor of Medicine, Harvard T.H. Chan School of Public Health Publishes: Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function. This major plasma gelsolin advancement was published in May in Journal of American Physiology—Lung, Cellular and Molecular Physiology.

Read article here.

July 1, 2015: BioAegis Therapeutics Collaboration with Harvard School of Public Health Discovers Plasma Gelsolin Boosts the Immune Response to Pathogens

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

EVENTS

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

COMPANY DETAILS

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US